Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.
Debora Bastos MelloFernanda Cristina Paccola MesquitaDanúbia Silva Dos SantosKarina Dutra AsensiMarlon Lemos DiasAntonio Carlos Campos de CarvalhoRegina Coeli Dos Santos GoldenbergTais Hanae Kasai-BrunswickPublished in: International journal of molecular sciences (2024)
Mesenchymal stromal cell (MSC)-based advanced therapy medicinal products (ATMPs) are being tried in a vast range of clinical applications. These cells can be isolated from different donor tissues by using several methods, or they can even be derived from induced pluripotent stem cells or embryonic stem cells. However, ATMP heterogeneity may impact product identity and potency, and, consequently, clinical trial outcomes. In this review, we discuss these topics and the need to establish minimal criteria regarding the manufacturing of MSCs so that these innovative therapeutics may be better positioned to contribute to the advancement of regenerative medicine.
Keyphrases
- bone marrow
- single cell
- clinical trial
- embryonic stem cells
- induced pluripotent stem cells
- cell therapy
- stem cells
- induced apoptosis
- mesenchymal stem cells
- gene expression
- small molecule
- cell cycle arrest
- adipose tissue
- open label
- endoplasmic reticulum stress
- study protocol
- signaling pathway
- insulin resistance
- phase ii
- pi k akt